Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| PTPI | 3 | neutral | 2/10 | Robert Weinstein filed a Form 3 initial statement of beneficial ownership with the SEC, disclosing 636,004 shares of Pet | Jul 3, 2026 |
| DFTX | 144 | neutral | 2/10 | Two Definium Therapeutics officers (Matthew T. Wiley and Brandi Roberts) filed Form 144 notices on June 25, 2026, indica | Jul 3, 2026 |
| DYN | 144 | neutral | 2/10 | Atlas Venture Opportunity Fund I, L.P., a venture capital affiliate, filed a Form 144 indicating intent to sell 5,019 sh | Jul 3, 2026 |
| PRQR | 424B5 | mixed | 6/10 | ProQR is conducting a ~$50M underwritten public offering of 27.6M shares at $1.81, with a concurrent $9.2M private place | Jul 3, 2026 |
| MPLT | 3 | neutral | 2/10 | Troy Cox filed an initial statement of beneficial ownership (Form 3) with the SEC, indicating he has become a director, | Jul 3, 2026 |
| FTLF | DEFA14A | neutral | 3/10 | FitLife Brands filed a DEFA14A (additional definitive proxy soliciting materials) on June 26, 2026. The filing contains | Jul 3, 2026 |
| TPST | S-3 | bearish | 5/10 | Tempest Therapeutics filed an S-3 registration statement to register 2,426,897 shares of common stock for resale by sell | Jul 3, 2026 |
| CLNV | 15-12G | bearish | 7/10 | Clean Vision Corp (CLNV) filed Form 15-12G to voluntarily terminate its SEC registration and suspend reporting obligatio | Jul 3, 2026 |
| GNTA | 6-K | neutral | 4/10 | Genenta discloses an Italian court order upholding its multiple-voting-rights structure but suspending an October 2025 r | Jul 3, 2026 |
| BCTX | 8-K | neutral | 2/10 | BriaCell Therapeutics Corp. disclosed the unaudited financial statements of its subsidiary BriaPro Therapeutics Corp. fo | Jul 3, 2026 |
| SYRE | S-3ASR | neutral | 5/10 | { "summary": "Spyre Therapeutics filed an automatic shelf registration statement (S-3ASR) on June 26, 2026, registerin | Jul 3, 2026 |
| PCVX | 144 | neutral | 3/10 | CEO Grant Pickering filed a Form 144 notice of intent to sell 24,237 shares of Vaxcyte (PCVX) with an approximate market | Jul 3, 2026 |
| MNPR | 8-K | bullish | 6/10 | Monopar presented new Phase 3 FoCus analyses showing ALXN1840 significantly improved neurologic and global clinical outc | Jul 3, 2026 |
| UPC | 6-K | bearish | 6/10 | Universe Pharmaceuticals (UPC) announced a share purchase agreement to acquire 100% of Best Praise International Limited | Jul 3, 2026 |
| SNGX | 8-K | bearish | 6/10 | Soligenix filed a prospectus supplement to increase its at-the-market (ATM) equity offering capacity by $2.5 million, br | Jul 3, 2026 |
| ATRA | 8-K | neutral | 3/10 | Atara Biotherapeutics disclosed the departure of Chief Accounting Officer Yanina Grant-Huerta (effective July 17, 2026) | Jul 3, 2026 |
| PDSB | DEFA14A | neutral | 3/10 | PDS Biotechnology Corp filed a DEFA14A, which is additional definitive proxy soliciting material. The document body is a | Jul 3, 2026 |
| ATAI | 144 | neutral | 3/10 | Gerd Kochendoerfer, an officer of AtaiBeckley Inc. (ATAI), filed a Form 144 on June 26, 2026, indicating intent to sell | Jul 3, 2026 |
| ERNA | 8-K | neutral | 3/10 | Ernexa Therapeutics disclosed the resignation of Sandra Gurrola, Senior Vice President of Finance, effective July 3, 202 | Jul 3, 2026 |
| ZSQR | S-1 | bearish | 5/10 | Z Squared Inc. filed an S-1 registration statement to register 100,000 shares (0.19% of outstanding) for resale by Deere | Jul 3, 2026 |
| RKDA | S-3 | bearish | 6/10 | Arcadia Biosciences filed an S-3 registration statement to register 11,922,333 shares of common stock for resale by sell | Jul 3, 2026 |
| JUNS | S-1 | neutral | 5/10 | { "summary": "Jupiter Neurosciences filed an S-1 registration statement to register 16,000,000 additional shares for r | Jul 3, 2026 |
| ANAB | 144 | bearish | 6/10 | CEO Dennis Mulroy filed a Form 144 on June 26, 2026, indicating intent to sell 10,000 shares of AnaptysBio common stock, | Jul 3, 2026 |
| KYMR | 144 | bearish | 6/10 | Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P. filed paired Form 144 notices on June 26, 2026, si | Jul 3, 2026 |
| DYN | 144 | neutral | 3/10 | Atlas Venture Opportunity Fund I, L.P., a major early investor, filed a Form 144 notice of intent to sell 64,411 shares | Jul 3, 2026 |
| ASRT | 15-12G | neutral | 6/10 | Assertio Holdings filed a Form 15-12G to terminate its SEC registration, citing only one holder of record. This typicall | Jul 3, 2026 |
| AMRX | DEFM14A | neutral | 6/10 | Amneal is soliciting stockholder approval for its acquisition of Kashiv BioSciences, a vertically integrated biosimilars | Jul 3, 2026 |
| IKT | 8-K | neutral | 3/10 | Inhibikase Therapeutics held its 2026 Annual Meeting on June 26, 2026, where stockholders approved an amendment to the 2 | Jul 3, 2026 |
| AZN | 6-K | bullish | 6/10 | AstraZeneca's Datroway (datopotamab deruxtecan) received a positive CHMP opinion recommending EU approval as 1st-line mo | Jul 3, 2026 |
| RMTI | 8-K | neutral | 2/10 | Rockwell Medical filed an 8-K announcing a 1-for-10 reverse stock split effective July 1, 2026, approved by stockholders | Jul 3, 2026 |